New drugs in ovarian cancer

摘要

Over the last decade, ovarian cancer prognosis has improved very modestly. According to the Surveillance, Epidemiology, and End Results program, the 5-year relative survival for ovarian cancer in the United States has only improved from 33.6% in 1975 to 45.2% in 2006, and the rate has not changed since. These advances are most likely from surgery and platinum-based therapy. Other than 2 very recent US Food and Drug Administration (FDA) approvals—for olaparib (Lynparza, AstraZeneca) and bevacizumab (Avastin, Genentech)—there have not been any new therapies approved for ovarian cancer in almost 10 years. Furthermore, neither olaparib nor bevacizumab is FDA-approved for frontline use.